Targeted therapies: BREAKing a path for progress - Dabrafenib confirms class effect

Hussein A. Tawbi; John M. Kirkwood

doi:10.1038/nrclinonc.2012.138

Targeted therapies: BREAKing a path for progress - Dabrafenib confirms class effect

Hussein A. Tawbi, John M. Kirkwood

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Dabrafenib is the second agent in the therapeutic class of selective BRAF inhibitors, and has proven efficacy in a phase III trial (BREAK-3) with impressive improvements in progression-free survival and response rates. Differences in the safety profile exist compared with vemurafenib, but the future lies in combinatorial strategies and improved patient selection.

Original language	English (US)
Pages (from-to)	496-497
Number of pages	2
Journal	Nature Reviews Clinical Oncology
Volume	9
Issue number	9
DOIs	https://doi.org/10.1038/nrclinonc.2012.138
State	Published - Sep 2012
Externally published	Yes

ASJC Scopus subject areas

Oncology

Access to Document

10.1038/nrclinonc.2012.138

Cite this

@article{396093d430c44e1fb2b8ffda5a9a0a0c,

title = "Targeted therapies: BREAKing a path for progress - Dabrafenib confirms class effect",

abstract = "Dabrafenib is the second agent in the therapeutic class of selective BRAF inhibitors, and has proven efficacy in a phase III trial (BREAK-3) with impressive improvements in progression-free survival and response rates. Differences in the safety profile exist compared with vemurafenib, but the future lies in combinatorial strategies and improved patient selection.",

author = "Tawbi, {Hussein A.} and Kirkwood, {John M.}",

year = "2012",

month = sep,

doi = "10.1038/nrclinonc.2012.138",

language = "English (US)",

volume = "9",

pages = "496--497",

journal = "Nature Reviews Clinical Oncology",

issn = "1759-4774",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - Targeted therapies

T2 - BREAKing a path for progress - Dabrafenib confirms class effect

AU - Tawbi, Hussein A.

AU - Kirkwood, John M.

PY - 2012/9

Y1 - 2012/9

N2 - Dabrafenib is the second agent in the therapeutic class of selective BRAF inhibitors, and has proven efficacy in a phase III trial (BREAK-3) with impressive improvements in progression-free survival and response rates. Differences in the safety profile exist compared with vemurafenib, but the future lies in combinatorial strategies and improved patient selection.

AB - Dabrafenib is the second agent in the therapeutic class of selective BRAF inhibitors, and has proven efficacy in a phase III trial (BREAK-3) with impressive improvements in progression-free survival and response rates. Differences in the safety profile exist compared with vemurafenib, but the future lies in combinatorial strategies and improved patient selection.

UR - http://www.scopus.com/inward/record.url?scp=84865701482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865701482&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2012.138

DO - 10.1038/nrclinonc.2012.138

M3 - Review article

C2 - 22889973

AN - SCOPUS:84865701482

SN - 1759-4774

VL - 9

SP - 496

EP - 497

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

IS - 9

ER -

Targeted therapies: BREAKing a path for progress - Dabrafenib confirms class effect

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this